1. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study
- Author
-
Alessio Buonaiuto, Maria Donata Di Taranto, Ilenia Calcaterra, Marco Gentile, Paolo Rubba, Giuliana Fortunato, Carola Giacobbe, M. Tripaldella, Matteo Nicola Dario Di Minno, Gabriella Iannuzzo, Francesco Forte, Iannuzzo, G., Buonaiuto, A., Calcaterra, I., Gentile, M., Forte, F., Tripaldella, M., Di Taranto, M. D., Giacobbe, C., Fortunato, G., Rubba, P. O., and Di Minno, M. N. D.
- Subjects
Adult ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Familial hypercholesterolemia ,Medicine (miscellaneous) ,medicine.disease_cause ,Single Center ,Gastroenterology ,Hyperlipoproteinemia Type II ,Proprotein convertase subtilisin/kexin type 9 inhibitors ,Internal medicine ,Humans ,Medicine ,Low-density lipoprotein cholesterol ,Aged ,Mutation ,Nutrition and Dietetics ,business.industry ,PCSK9 ,PCSK9 Inhibitors ,Autosomal dominant trait ,Middle Aged ,Proprotein convertase ,medicine.disease ,Receptors, LDL ,Low-density lipoprotein receptor gene ,LDL receptor ,Kexin ,lipids (amino acids, peptides, and proteins) ,Proprotein Convertase 9 ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background and Aims Familial hypercholesterolemia (FH) is an autosomal dominant disease that leads to cardiovascular (CV) disease. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-I) demonstrated efficacy in low-density lipoprotein cholesterol (LDL-C) reduction and in prevention of CV events. The aim of our study is to evaluate the relationship between LDL receptor (LDLR) mutations and response to PCSK9-I therapy. Methods and Results We evaluated total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) in consecutive patients with FH before PCSK9-I treatment and after 12 (T12w) and 36 (T36w) weeks of treatment. We evaluated LDL-C target achievement according to different mutations in LDLR. Eighty FH subjects (mean age:54±13.3 years), 39 heterozygous (He) with defective LDLR gene mutations, 30 He with null mutations and 11 compound-He or homozygotes (Ho) were recruited. At baseline, 69 subjects were under maximal lipid lowering therapy (MLLT) and 11 subjects had statin-intolerance. From baseline to T36w we observed an overall 51% reduction in LDL-C. We found no difference in LDL-C changes between subjects with He-defective mutation and He-null mutations both at T12w (p=1.00) and T36w (p=0.538). At T36w, LDL-C target was achieved in 59% of He-defective mutations subjects and in 36% of He-null mutations subgroup (p=0.069), whereas none of compound-He/Ho-FH achieved LDL-C target. Conclusions After 36 weeks there were no differences in response to PCSK9-I therapy between different groups of He-FH subjects. Response to PCSK9-I was significantly lower in carriers of compound-He/Ho mutations. Registration number for clinical trials: NCT04313270 extension.
- Published
- 2022